首页> 美国卫生研究院文献>Antioxidants >Toxicity of Antioxidant Supplements in Patients with Male Factor Infertility: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
【2h】

Toxicity of Antioxidant Supplements in Patients with Male Factor Infertility: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

机译:抗氧化剂补充剂对男性因素不育症患者的毒性:随机对照试验的系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Treating oxidative stress through antioxidant therapy has been considered an appealing strategy in the management of male infertility. However, evidence regarding the toxicity of antioxidant therapy is controversial. We summarized the available clinical evidence on the toxicity associated with the use of antioxidants in infertile males. A systematic review was performed in March 2021. We included randomized controlled trials evaluating the incidence of adverse events in male patients with infertility receiving antioxidant therapy. Thirteen studies involving 1999 male patients were identified. Antioxidant supplementation in patients with male factor infertility was associated with a statistically significantly increased risk of nausea (Odds Ratio: 2.16, 95% Confidence Interval: 1.05–4.43, p = 0.036), headache (Odds Ratio: 3.05, 95% Confidence Interval: 1.59– 5.85 p = 0.001), and dyspepsia (Odds Ratio: 4.12, 95% Confidence Interval: 1.43–11.85, p = 0.009) compared to a placebo. Treatment discontinuation due to adverse events was not significantly higher in patients taking antioxidants compared to a placebo (Odds Ratio: 2.29, 95% Confidence Interval: 0.76–6.88, p = 0.139). When antioxidant supplementation is considered, a more accurate risk/benefit analysis is warranted.
机译:通过抗氧化疗法治疗氧化应激被认为是管理男性不育症的一种有吸引力的策略。然而,关于抗氧化疗法毒性的证据存在争议。我们总结了关于不育男性使用抗氧化剂相关毒性的现有临床证据。2021 年 3 月进行了系统评价。我们纳入了评估接受抗氧化治疗的男性不孕症患者不良事件发生率的随机对照试验。确定了 13 项研究,涉及 1999 名男性患者。与安慰剂相比,男性因素不育患者补充抗氧化剂与恶心风险增加(比值比:2.16,95% 置信区间:1.05-4.43,p = 0.036)、头痛(比值比:3.05,95% 置信区间:1.59-5.85 p = 0.001)和消化不良(比值比:4.12,95% 置信区间:1.43-11.85,p = 0.009)的风险显著增加相关。与安慰剂相比,服用抗氧化剂的患者因不良事件而停止治疗的情况并未显著升高(比值比:2.29,95% 置信区间:0.76-6.88,p = 0.139)。当考虑抗氧化剂补充剂时,需要更准确的风险/获益分析。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号